Demonstrates improved anti-tumor efficacy in solid tumors using engineered iPSC-derived T cells, suggesting advances in immunotherapy.
memory T cell-like phenotype in tumors, contributing to the prolonged survival of the animal model. These findings demonstrate that cytokine synergy can be engineered into iPSC-derived T cells to overcome significant barriers in solid tumor immunotherapy, offering a scalable approach to developing next-generation off-the-shelf CAR-T therapies.
No takes yet. Share an insight, caveat, or question.
Ishikawa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: